105 related articles for article (PubMed ID: 10754999)
1. Molecular markers for colon cancer: where do we go from here?
Kulesz-Martin M
Cancer Invest; 2000; 18(3):287-8. PubMed ID: 10754999
[No Abstract] [Full Text] [Related]
2. Staging of colon and rectal cancer: from endoscopy to molecular markers.
Greene FL
Surg Endosc; 2006 Apr; 20 Suppl 2():S475-8. PubMed ID: 16544060
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer.
Smyth EF; Sharma A; Sivarajasingham N; Hartley J; Monson JR; Cawkwell L
Dis Colon Rectum; 2004 Dec; 47(12):2086-91; discussion 2091-2. PubMed ID: 15657659
[TBL] [Abstract][Full Text] [Related]
4. Molecular characteristics of cancers: the way of the future?
Mutch DG
Gynecol Oncol; 2000 Apr; 77(1):8-10. PubMed ID: 10739684
[No Abstract] [Full Text] [Related]
5. TP53 mutation and microsatellite instability status for the prediction of survival in adjuvant-treated colon cancer patients.
Watanabe T; Kanazawa T; Kazama Y; Tanaka J; Tanaka T; Ishihara S; Nagawa H
J Clin Oncol; 2005 Dec; 23(35):9031-2; author reply 9032-3. PubMed ID: 16339756
[No Abstract] [Full Text] [Related]
6. [Which histo-prognostic factors are useful for a therapeutic decision in colon cancer?].
Piard F; Monges G
Ann Pathol; 1998 Nov; 18(5):404-14. PubMed ID: 9864576
[No Abstract] [Full Text] [Related]
7. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers.
Vécsey-Semjén B; Becker KF; Sinski A; Blennow E; Vietor I; Zatloukal K; Beug H; Wagner E; Huber LA
Oncogene; 2002 Jul; 21(30):4646-62. PubMed ID: 12096341
[TBL] [Abstract][Full Text] [Related]
8. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
9. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
10. Proliferative activity and loss of function of tumour suppressor genes as 'biomarkers' in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma.
Girod SC; Pfeiffer P; Ries J; Pape HD
Br J Oral Maxillofac Surg; 1998 Aug; 36(4):252-60. PubMed ID: 9762452
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
12. Negative CDX2 expression can be an important predictive and prognostic biomarker in stage II colon cancer.
Bilgin B; Sendur MA; Akinci MB; Yalcin B
J BUON; 2017; 22(1):282-283. PubMed ID: 28365970
[No Abstract] [Full Text] [Related]
13. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma.
Elsaleh H; Powell B; Soontrapornchai P; Joseph D; Goria F; Spry N; Iacopetta B
Oncology; 2000; 58(1):52-9. PubMed ID: 10644941
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma.
Bhatavdekar JM; Patel DD; Ghosh N; Chikhlikar PR; Trivedi TI; Suthar TP; Doctor SS; Shah NG; Balar DB
Dis Colon Rectum; 1997 Jul; 40(7):785-90. PubMed ID: 9221853
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of oncogenesis in colon versus rectal cancer.
Kapiteijn E; Liefers GJ; Los LC; Kranenbarg EK; Hermans J; Tollenaar RA; Moriya Y; van de Velde CJ; van Krieken JH
J Pathol; 2001 Sep; 195(2):171-8. PubMed ID: 11592095
[TBL] [Abstract][Full Text] [Related]
17. Staging of renal cell carcinoma: current concepts.
Shvarts O; Lam JS; Kim HL; Belldegrun AS
BJU Int; 2005 Mar; 95 Suppl 2():8-13. PubMed ID: 15759349
[No Abstract] [Full Text] [Related]
18. Heat shock protein and p53 expression in head and neck squamous cell carcinoma.
Gandour-Edwards R; Trock BJ; Gumerlock P; Donald PJ
Otolaryngol Head Neck Surg; 1998 May; 118(5):610-5. PubMed ID: 9591858
[TBL] [Abstract][Full Text] [Related]
19. Colon cancer: p53 expression and DNA ploidy. Their relation to proximal or distal tumor site.
García-Hirschfeld García J; Blanes Berenguel A; Vicioso Recio L; Márquez Moreno A; Rubio Garrido J; Matilla Vicente A
Rev Esp Enferm Dig; 1999 Jul; 91(7):481-8. PubMed ID: 10477366
[TBL] [Abstract][Full Text] [Related]
20. The biological and clinicopathological characteristics of right-sided colon cancer.
Iwatani Y; Shimada Y; Seima Y; Yamazaki T; Miyazaki N
Oncol Rep; 2000; 7(5):991-4. PubMed ID: 10948328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
